The FDA granted approval to Cytokinetics' Myqorzo—the company’s first U.S. drug—for obstructive hypertrophic cardiomyopathy, marking a milestone after a nearly three‑decade effort. Cytokinetics plans commercial launch in late January; pricing has not been disclosed. Myqorzo will compete with an already approved Bristol Myers Squibb therapy that has generated more than $1 billion annualized sales. Cytokinetics positions the approval as validation of its cardiovascular discovery platform and a revenue driver to support further pipeline work. The approval reshapes the competitive landscape for inherited cardiomyopathies and gives Cytokinetics a commercial foothold that could fund additional R&D. Market observers will watch uptake against an entrenched BMS product and how payors place the new entrant into treatment algorithms.